Cargando…

Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients

BACKGROUND: Achievement of pathologic complete response (pCR) in breast cancer patients receiving neoadjuvant chemotherapy (NAC) is associated with both overall survival and disease-free survival. The aim of present study was to identify clinical and pathological factors associated with achieving pC...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasanpour, Pegah, Sandoughdaran, Saleh, Mosavi-Jarrahi, Alireza, Malekzadeh, Mona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249452/
https://www.ncbi.nlm.nih.gov/pubmed/30255695
http://dx.doi.org/10.22034/APJCP.2018.19.9.2423
_version_ 1783372752613277696
author Sasanpour, Pegah
Sandoughdaran, Saleh
Mosavi-Jarrahi, Alireza
Malekzadeh, Mona
author_facet Sasanpour, Pegah
Sandoughdaran, Saleh
Mosavi-Jarrahi, Alireza
Malekzadeh, Mona
author_sort Sasanpour, Pegah
collection PubMed
description BACKGROUND: Achievement of pathologic complete response (pCR) in breast cancer patients receiving neoadjuvant chemotherapy (NAC) is associated with both overall survival and disease-free survival. The aim of present study was to identify clinical and pathological factors associated with achieving pCR in Iranian breast cancer patients receiving NAC. METHODS: A retrospective review of all breast cancer patients treated with neoadjuvant chemotherapy between April 2012 and September 2016 at our institution was performed; 207 cases were evaluable for analysis. pCR was defined as having no residual invasive tumor in the breast surgical specimen removed following neoadjuvant therapy. RESULTS: In univariate analysis, factors associated with pCR were age less than 35 years (p = 0.03), absence of Lymphovascular invasion (LVI) (p = 0.002) and negative hormone receptor status (p = 0.003). Hormone receptor status (P = 0.01; OR, 2.45; CI, 1.20 - 4.99) and LVI (P = 0.001; OR, 0.22; CI, 0.10 - 0.46) remained predictive variables in multivariate analysis after correction for the other variables. CONCLUSIONS: In conclusion, the results of this study suggests that presence of Lymphovascular invasion and positive hormone receptor status are associated with poorer response to neoadjuvant chemotherapy in breast cancer patients.
format Online
Article
Text
id pubmed-6249452
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-62494522018-12-07 Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients Sasanpour, Pegah Sandoughdaran, Saleh Mosavi-Jarrahi, Alireza Malekzadeh, Mona Asian Pac J Cancer Prev Research Article BACKGROUND: Achievement of pathologic complete response (pCR) in breast cancer patients receiving neoadjuvant chemotherapy (NAC) is associated with both overall survival and disease-free survival. The aim of present study was to identify clinical and pathological factors associated with achieving pCR in Iranian breast cancer patients receiving NAC. METHODS: A retrospective review of all breast cancer patients treated with neoadjuvant chemotherapy between April 2012 and September 2016 at our institution was performed; 207 cases were evaluable for analysis. pCR was defined as having no residual invasive tumor in the breast surgical specimen removed following neoadjuvant therapy. RESULTS: In univariate analysis, factors associated with pCR were age less than 35 years (p = 0.03), absence of Lymphovascular invasion (LVI) (p = 0.002) and negative hormone receptor status (p = 0.003). Hormone receptor status (P = 0.01; OR, 2.45; CI, 1.20 - 4.99) and LVI (P = 0.001; OR, 0.22; CI, 0.10 - 0.46) remained predictive variables in multivariate analysis after correction for the other variables. CONCLUSIONS: In conclusion, the results of this study suggests that presence of Lymphovascular invasion and positive hormone receptor status are associated with poorer response to neoadjuvant chemotherapy in breast cancer patients. West Asia Organization for Cancer Prevention 2018 /pmc/articles/PMC6249452/ /pubmed/30255695 http://dx.doi.org/10.22034/APJCP.2018.19.9.2423 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Research Article
Sasanpour, Pegah
Sandoughdaran, Saleh
Mosavi-Jarrahi, Alireza
Malekzadeh, Mona
Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients
title Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients
title_full Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients
title_fullStr Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients
title_full_unstemmed Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients
title_short Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients
title_sort predictors of pathological complete response to neoadjuvant chemotherapy in iranian breast cancer patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249452/
https://www.ncbi.nlm.nih.gov/pubmed/30255695
http://dx.doi.org/10.22034/APJCP.2018.19.9.2423
work_keys_str_mv AT sasanpourpegah predictorsofpathologicalcompleteresponsetoneoadjuvantchemotherapyiniranianbreastcancerpatients
AT sandoughdaransaleh predictorsofpathologicalcompleteresponsetoneoadjuvantchemotherapyiniranianbreastcancerpatients
AT mosavijarrahialireza predictorsofpathologicalcompleteresponsetoneoadjuvantchemotherapyiniranianbreastcancerpatients
AT malekzadehmona predictorsofpathologicalcompleteresponsetoneoadjuvantchemotherapyiniranianbreastcancerpatients